Xeloda and Abraxane for pancreatic cancer
Xeloda has some activity alone in pancreatic cancer. Mostof what we know about Xeloda in this cancer, is known about combining it with gemcitabine. Less is know about combining it with Abraxane. In 2009, Abraxane was given orphan status for the treatment of pancreatic cancer and Stage IIB-IV melanoma. An orphan designation means that the FDA sees a need to investigate a drug for a specified indication.
There had been no trials or publications of Xeloda and Abraxane for pancreatic cancer, as far as I could determine. The GAX combination is in a clinical trial: Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma, NCT01161186. The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer. The trial was completed and awaits publication.
For Professional version see here